Tracking of menstrual cycles and prediction of diminished ovarian reserve via wearable devices Urological and Genital Diseases
Conditions
Interventions
The study is conducted by online questionnaire survey, and the personal information of the participants will be kept confidential. The study involves tracking menstrual cycles and prediction of dimini
Huawei Device Co, Ltd, Shenzhen, China), and a smartphone (Huawei Mate 30
Huawei Device Co, Ltd, Shenzhen, China) to record essential physiological data. Participants with regular menstrual cycles (adhering to FIGO 2018) will be followed up through two menstrual cycles, and
Sponsors
Obstetrics and Gynecology Hospital of Fudan University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Aged 18-45 years old 2. AMH < 1.1 ng/mL 3. Menstruation within at least 6 months 3. Willing to participate in the follow-up and sign the informed consent
Exclusion criteria
Exclusion criteria: 1. Menopause, pregnancy, lactation 2. Exogenous hormones within 3 months, history of ovarian surgery, planned exogenous hormone therapy 3. Suffering from other states or diseases that can affect heart rate, respiration, body temperature and sleep parameters: diseases of the cardiovascular system (hypertension, heart disease, arrhythmia, wearing a pacemaker, etc.), respiratory diseases, abnormalities of the thyroid function (hyperthyroidism/hypothyroidism, positive antibodies are not excluded), taking psychotropic medications 4. Severe systemic disease or any unstable disease or medical condition that, according to medical criteria, may jeopardize patient safety and his/her compliance with the requirements of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fertility measured using a serum anti-mullerian hormone (AMH) blood test at baseline, which is determined on the 2nd-4th day of menstruation for patients with a regular menstrual cycle, and on any day for those with irregular menstrual cycle | — |
Secondary
| Measure | Time frame |
|---|---|
| Fertility measured using a basal hormone blood test (FSH, LH, E2, P, PRL, T, DHEA) at baseline and > 4 weeks, which is determined on the 2nd-4th day of menstruation for patients with regular menstrual cycle, and on any day for those with irregular menstrual cycle | — |
Countries
China
Contacts
Public ContactYalong Liu
Outcome results
None listed